Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketamine sublingual - iX Biopharma

Next Previous
Drug Profile

Ketamine sublingual - iX Biopharma

Alternative Names: Ketamine wafer - iX Biopharma; SLS-003; Wafermine

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator iX Biopharma
  • Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Neuroprotectants; Obesity therapies; Small molecules
  • Mechanism of Action AMPA receptor agonists; Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Complex regional pain syndromes
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute pain; Dental pain; Pain
  • No development reported Depressive disorders

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Depressive disorders in Singapore (Sublingual, Wafer)
  • 24 Nov 2021 Ketamine sublingual licensed to Seelos Therapeutics worldwide (excluding China, Taiwan, Macau and Hong Kong) for the treatment/prevention of chronic neuropathic pain, complex regional pain syndrome, psychiatric disorders, and post-traumatic stress disorder
  • 15 Jun 2021 ix Biopharma and Chris O’Brien Lifehouse plan a clinical trial in Pain (as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain) in Australia (Sublingual, Wafer)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top